N-Terminomics TAILS identifies host cell substrates of poliovirus and coxsackievirus B3 3C proteinases that modulate virus infection

Julienne M Jagdeo¹,², Antoine Dufour²,³, Theo Klein²,³, Nestor Solis²,³, Oded Kleifeld⁵, Jayachandran Kizhakkedathu⁴, Honglin Luo⁴, Christopher M Overall¹,²,³ and Eric Jan¹,²*

¹Department of Biochemistry and Molecular Biology, ²Life Sciences Institute, ³Centre for Blood Research, Faculty of Dentistry, Department of Oral Biological and Medical Sciences and ⁴Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada ⁵School of Biomedical Sciences, Monash University, Victoria, Australia

Running Head: Host cell substrates of enterovirus 3C\textsuperscript{pro}

*corresponding author: ej@mail.ubc.ca
Abstract

Enteroviruses encode proteinases that are essential for processing of the translated viral polyprotein. In addition, viral proteinases also target host proteins to manipulate cellular processes and evade innate antiviral responses to promote replication and infection. Although some host protein substrates of enterovirus proteinases have been identified, the full repertoire of targets remains unknown. We used a novel quantitative in vitro proteomics-based approach, termed terminal amine isotopic labeling of substrates (TAILS), to identify with high confidence 72 and 34 new host protein targets of poliovirus and coxsackievirus B3 (CVB3) 3C proteinases (3Cpro) in HeLa cell and cardiomyocyte HL-1 cell lysates, respectively. We validated a subset of candidate substrates that are targets of poliovirus 3Cpro in vitro including three common protein targets, PFAS, hnRNP K and hnRNP M, of both proteinases. 3Cpro-targeted substrates were also cleaved in virus-infected cells, but not noncleavable mutant proteins designed from the TAILS-identified cleavage sites. Knockdown of TAILS-identified target proteins modulated infection both negatively and positively suggesting that cleavage by 3Cpro promotes infection. Indeed, expression of a cleavage-resistant mutant form of the ER-Golgi vesicle tethering protein p115 decreased viral replication and yield. As the first comprehensive study to identify and validate functional enterovirus 3Cpro substrates in vivo, we conclude that N-terminomics by TAILS is an effective strategy to identify host targets of viral proteinases in a nonbiased manner.
Importance

Enteroviruses are positive-strand RNA viruses that encode proteases that cleave the viral polyprotein into the individual mature viral proteins. In addition, viral proteases target host proteins in order to modulate cellular pathways and block antiviral responses in order to facilitate virus infection. Although several host protein targets have been identified, the entire list of proteins that are targeted is not known. In this study, we used novel unbiased proteomics approach to identify ~100 novel host targets of the enterovirus 3C protease, thus providing further insights into the network of cellular pathways that are modulated to promote virus infection.
Introduction

Proteases regulate numerous cellular processes through cleavage of their substrates (1). Several classes of viruses encode proteinases that function in processing and maturation of viral proteins for the synthesis of new virus particles. In addition, viral proteinases can target a subset of host proteins to modulate cellular processes that facilitate virus infection (2). Viral proteinases have been well-characterized among the picornavirus family, which include members of the enterovirus genus, poliovirus and coxsackievirus B3 (CVB3). Enterovirus infections can cause a wide range of diseases, from respiratory ailments to paralysis and dilated cardiomyopathy, to which there are no effective antiviral therapies (3-5).

Picornaviruses possess a positive-sense single-stranded RNA genome approximately ~7.5 kb in length that contain a single open reading frame (6-8). A highly structured internal ribosome entry site (IRES) within the 5' untranslated region (UTR) directs viral translation to produce a single polyprotein, which is then processed into individual mature viral proteins by at least one virally-encoded proteinase. During infection, processing of the viral polyprotein occurs through a coordinated sequence of cleavage events in a site-specific and temporally regulated manner (9). The 3C proteinase (3C\textsuperscript{pro}), a chymotrypsin-like protease with a cysteine nucleophile, is conserved among all known picornaviruses (10, 11). 3C\textsuperscript{pro} in its precursor form as 3CD\textsuperscript{pro} is responsible for the majority of the viral polyprotein cleavages, targeting distinct glutamine-glycine residues with a preferred consensus cleavage motif of A\textbullet X\textbullet X\bullet Q\downarrow G\textbullet P\textbullet X\textbullet X,
where X denotes any amino acid and "↓" represents the scissile bond between P1`-P4` and P1-P4 residues, respectively (12). The enterovirus genus of picornaviruses encode a second proteinase, the 2A proteinase ($2A^{\text{pro}}$), that performs minor cleavage events within the polyprotein. Similar to $3C^{\text{pro}}$, $2A^{\text{pro}}$ bears a chymotrypsin-like structure with a cysteine nucleophile, and mediates a single cleavage event within the polyprotein at its N-terminus between specific tyrosine-glycine residues (13).

The identification of several host targets of picornaviral proteinases have provided insights into the fundamental virus-host interactions and the viral strategies utilized to modulate and usurp host processes to facilitate specific steps of the viral life cycle. The classic example is cleavage of the translation initiation factor, eukaryotic initiation factor 4G (eIF4G), by $2A^{\text{pro}}$, which contributes to the shutoff of host translation, a prominent characteristic of many picornavirus infections that serves to inhibit induction of host antiviral responses and favor viral IRES-mediated translation (14-16). Enterovirus proteinases also target proteins involved in transcription, nuclear import, RNA metabolism, and antiviral innate immune response signaling (17, 18). The functions of many of these host proteins are hijacked to support various steps in the life cycle, which can be regulated through cleavage. For example, in poliovirus-infected cells, relocalized poly(rC) binding protein 2 (PCBP2, also called hnRNP E2) and polypyrimidine tract binding protein (PTB, also called hnRNP I) bind to distinct regions within the viral 5’UTR to promote viral translation (19-22). As infection progresses, a switch
from viral translation to replication occurs whereby PCBP2 and PTB are cleaved by 3C\textsuperscript{pro}, thus disrupting their ability to facilitate virus translation.

Currently, there are ~54 known host targets of picornavirus proteinases (17). Most targets have been identified through candidate approaches, 2-D gel electrophoresis coupled with mass spectrometry, and bioinformatics based on a search for consensus cleavage sites (21, 23-26). However, these techniques have several limitations and biases (27). Bioinformatics and candidate approaches are hypothesis driven that may not fully capture physiologically-relevant protease substrates, and 2D-gel electrophoresis followed by mass spectrometry is older technology that has limited resolution and coverage, and may miss low abundance target proteins. To overcome these limitations, recent advances in mass spectrometry-based techniques have developed gel-free strategies that identify protease-generated peptides (28-30). One such approach dedicated for the enrichment of protease cleavage products is terminal amine isotopic labeling of substrates (TAILS). Protease-generated N-termini (neo-N-termini) peptides are purified by negative selection and then identified by tandem mass spectrometry (30). The advantage of TAILS is that minimal amounts of lysate are required, and identification of the cleaved peptide by mass spectrometry analysis simultaneously identifies the protein and the actual cleavage site. TAILS has successfully identified novel substrates for several cellular proteases (31-34). Here we applied TAILS to identify novel substrates of the picornavirus proteinase 3C\textsuperscript{pro} from enteroviruses, poliovirus and CVB3. We identified multiple high confidence candidate substrates of poliovirus and CVB3.
3C\textsuperscript{pro}, respectively and validated several \textit{in vitro} and in infection. Three candidate substrates were found in common, which were identified at the same cleavage site, suggesting that they may be strategic targets for enterovirus infection. Moreover, siRNA-mediated depletion studies revealed functional significance of candidate targets in promoting poliovirus infection.
Results

TAILS identification of candidate substrates of poliovirus and CVB3 3C\textsuperscript{pro} in vitro

Although ~40 substrates of picornavirus 3C\textsuperscript{pro} are known, we hypothesized that 3C\textsuperscript{pro} targets other host substrates that have yet to be identified (17). To address this, we applied an in vitro TAILS approach using proteinases from two model enteroviruses, poliovirus and CVB3 3C\textsuperscript{pro} (Fig. 1A).

An in vitro approach was chosen in order to identify direct host targets of the viral proteinases and is a simple approach that has been used successfully to identify bona fide substrates (29, 30, 35, 36). Poliovirus and CVB3 3C proteinases were chosen as they have been extensively studied at the biochemical and structural levels, thus conditions for cleavage are known (11, 37, 38). Moreover, as a subset of host targets are known, they can be used to benchmark the success of TAILS. Briefly, proteome samples were prepared from HeLa cell extracts and incubated with purified wild type or a catalytically inactive mutant (Cys147Ala, hereafter referred as C147A) recombinant poliovirus 3C\textsuperscript{pro}. For comparison, proteome samples from HL-1 cardiomyocyte lysates were incubated with CVB3 wild type or catalytically inactive (C147A) recombinant 3C\textsuperscript{pro} in order to more closely recapitulate a physiological setting of CVB3 infection (4, 5). CVB3 is a clinically relevant virus that contributes to viral myocarditis and dilated cardiomyopathy (39). TAILS analysis of proteinases from two different enteroviruses that infect distinct cell lines may identify common and tissue-
specific host targets that may be important for general enterovirus infection, including those that may contribute to specific pathogenesis of disease.

Incubation of wild type but not mutant 3C\textsuperscript{pro} in lysates resulted in cleavage of known target substrates poly(A) binding protein (PABP), ras GTPase-activating protein- binding protein 1 (G3BP1) and TAR DNA-binding protein 43 (TDP-43), thus confirming that the purified recombinant 3C\textsuperscript{pro} is active (Fig. 2) (40-44). TAILS was performed on cellular extracts using conditions previously optimized for proteolytic activity (Fig. 2) (29, 30, 45). Following proteinase digestion, samples were isotopically-labeled by reductive dimethylation of primary amines, applying a isotopically heavy (+6 Da) or medium (+4 Da) (defined as H) formaldehyde to the wild type sample versus a light (L) formaldehyde to the catalytically inactive (C147A) 3C\textsuperscript{pro} mutant sample (Fig. 1A).

The samples were mixed and trypsinized, followed by a negative selection step using a dendritic aldehyde polymer that removes trypsin-generated N-terminally unlabeled peptides, thus enriching for neo N-termini and natural N-termini peptides that were then identified by liquid chromatography tandem mass spectrometry (LC-MS/MS).

For poliovirus 3C\textsuperscript{pro}, TAILS-enriched peptides from HeLa cell lysates were analyzed from a total of 7 biological replicates using three different mass spectrometers and two search engines for peptide identification (Tables 1, S1-S4). From the 7 biological replicates, we identified 3482 total peptides, of which 3210 were unique peptides from 1965 unique proteins. For CVB3 3C\textsuperscript{pro}, using
three biological replicates, 347 unique peptides from 240 unique proteins were identified, from a total of 364 identified peptides (Tables 1 and S8).

Peptides with a high Heavy/Light (H/L) isotopic ratio (protease-treated/control) indicative of viral proteinase-generated cleaved peptides were identified and ranked to represent candidate substrates enriched for in lysates containing wild type 3C\textsuperscript{pro} compared to those containing mutant 3C\textsuperscript{pro} (Tables S5-6 and S9-S10). A box plot-and-whiskers analysis was applied to determine the high and low statistical isotopic H/L ratio cutoffs. Peptides with an H/L ratio above the high statistical ratio cutoff that were neo N-termini, representing peptides located internally within the protein, and contained an arginine at the C terminus (semi-tryptic) were selected as high confidence candidate substrates (Tables S5 and S9). For poliovirus 3C\textsuperscript{pro}, 72 high confidence candidate substrates were identified, including a peptide from isoform 2 of PTB, which is a known substrate of 3C\textsuperscript{pro} (Fig. 1C, Table S5) (20). Importantly, the PTB peptide identified by TAILS indicated that cleavage occurs between AIPQ↓AAGL\textsuperscript{318}, which is a previously reported cleavage site, thus providing validation of TAILS for 3C\textsuperscript{pro} (20). Although it was surprising that only one known substrate of enterovirus 3C\textsuperscript{pro} was identified by TAILS, predicted neo-N peptides of some known 3C\textsuperscript{pro} protein targets that would be generated by TAILS were either too short or too long for efficient ionization and fragmentation to allow confident identification by mass spectrometry (Table S12). An additional 78 natural N-termini or neo N-termini non-semi-tryptic peptides were identified with a H/L ratio above the statistical cut off (Table S6). Furthermore, we identified 165 neo N-termini and natural N-
termini peptides with a low H/L ratio indicative of degradative loss of this part of the molecule by the proteinase (Table S7).

The same approach for substrate winnowing was applied to identify 34 high confidence candidate substrates of CVB3 3C<sub>pro</sub>, as well as 10 natural N-termini or non semi-tryptic neo-N-termini peptides and 36 significantly low ratio (degraded) neo N-termini and natural N-termini peptides (Fig. 1D, Tables 1, S9-S11). Interestingly, three TAILS peptides were found common among both poliovirus and CVB3 3C<sub>pro</sub> lists of high confidence substrates: hnRNP K, hnRNP M and phosphoribosylformylglycinamidine synthase (PFAS) (Figs. 1B and 1E).

Gene Ontology (GO) analysis showed that the 3C<sub>pro</sub> high-confidence candidate protein targets are, in general, broadly distributed across many cellular pathways (ex. majority of pathways had only one target substrate) with a slight enrichment in apoptosis and ubiquitin proteasome signaling pathways (Table S13). This result is in line that 3C<sub>pro</sub> modulates a number of pathways to facilitate infection (17).

An analysis of the poliovirus 3C<sub>pro</sub> cleavage sites identified by TAILS revealed a strong preference for glutamine and alanine or valine at the P1 and P4 position, respectively, which is consistent with the consensus cleavage sequence previously derived from mutagenesis studies and peptide substrate analysis (Fig. 3A) (12). In addition, glycine, alanine, and serine were strongly preferred at the P1' position, similar to what was observed previously (46). However, additional preference for methionine and glutamine suggests there is further leniency at the P1' position. Similarly, analysis of CVB3 3C<sub>pro</sub> high
confidence substrate peptides shows preferences consistent with the known consensus cleavage sequence, with glutamine at P1, and glycine and alanine at P1' (Fig. 3B). Alanine was also observed at the P4 positions, along with additional amino acids that may be accommodated in these positions. Additional amino acid preferences were observed for both poliovirus and CVB3 3Cpro at other positions where substrate specificity is less well-characterized. In summary, TAILS identified several novel candidate substrates of 3Cpro and indicates that 3Cpro can accommodate a wider range of target cleavage sequences than previously reported.

Validation of candidate substrates in vitro

We chose both specific and random candidate substrates for further analysis based on identification in both PV and CVB3 3Cpro lists (i.e. hnRNP M and K, PFAS), their potential function in the viral life cycle (i.e. RIPK1 in inflammasome pathway, p115 and GBF1 in ER-Golgi transport pathway) and whether putative TAILS-identified cleavage site had a glutamine at the P1 position and had a statistically significant high heavy:light ratio (ex. ACLY, ALIX).

To confirm whether TAILS-identified candidate substrates are bona fide targets of 3Cpro, we monitored select substrates by immunoblotting following an in vitro cleavage assay. We previously validated and characterized hnRNP M as a novel substrate of poliovirus and CVB3 3Cpro, which we identified by TAILS of both poliovirus and CVB3 3Cpro (Fig. 1E) (45). Addition of recombinant poliovirus wild type, but not mutant 3Cpro in HeLa lysates resulted in cleaved PFAS, hnRNP K,
programmed cell death 6-interacting protein (ALIX), ATP-citrate synthase (ACLY), Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (GBF1) and receptor-interacting serine/threonine-protein kinase 1 (RIPK1) (Fig. 4), thereby validating the TAILS data. The mass of the cleavage fragments of PFAS, hnRNP K, ALIX, p115 and GBF1 identified by immunoblotting are consistent with the cleavage sites found by TAILS (Fig. 4). For example, the TAILS-generated peptide of hnRNP K predicts cleavage between $^{364}\text{Gln}\downarrow\text{Gly}^{365}$ to produce N- and C-terminal protein fragments of MW ~40.4 and ~11.0 kDa, respectively. Immunoblotting using the hnRNP K antibody detected an N-terminal cleavage fragment of ~40 kDa. Although the general vesicular transport factor p115 antibody that recognizes a C-terminal domain epitope showed a loss of full-length protein in lysates incubated with wild type 3C$^{\text{pro}}$, an N-terminal p115 antibody detected a cleaved N-terminal p115 fragment consistent with the TAILS-identified cleavage site. In contrast, immunoblotting of ACLY and RIPK1 detected different cleavage fragments than identified by TAILS, suggesting the existence of an alternative cleavage site that could not be identified by MS (e.g. the site was too close to an Arg rendering it redundant and therefore not considered further bioinformatically) or that 3C$^{\text{pro}}$ cleaves at multiple sites. Thus, we have identified seven additional novel protein targets of 3C$^{\text{pro}}$, in addition to hnRNP M, through TAILS.

To biochemically confirm the cleavage sites identified by TAILS, we generated target proteins that contained mutations at the P1 and P1' positions. We subcloned the wild type or mutant open reading frames into a mammalian
expression vector fused in frame with a 3xFLAG and 3xHA tag at the N- and C-
termini, respectively (Fig. 5A). Cell lysates from HeLa cells expressing either wild
type or mutant FLAG-HA constructs were subjected to an in vitro cleavage assay
using poliovirus 3C\textsuperscript{pro}. Incubation with wild type, but not catalytically inactive
(C147A) poliovirus 3C\textsuperscript{pro} resulted in cleavage of wild type FLAG-HA-tagged
PFAS, hnRNP K, ALIX, p115, RIPK1 and ACLY (Fig. 5B). In contrast, mutant
versions of these proteins, except for RIPK1 and ACLY, were not cleaved by
poliovirus 3C\textsuperscript{pro} at the mutated TAILS-identified cleavage site (Fig. 5B). For
FLAG-ACLY-HA, the FLAG antibody detected two cleavage products at ~63 kDa
and ~90 kDa (Fig. 5B). The larger ~90 kDa cleavage product, which is the
predicted mass of the N-terminal fragment based on the TAILS-identified
cleavage site, was not generated from the Gln777Glu/Ala778Pro FLAG-ACLY-
HA mutant. The smaller ~63 kDa cleavage product suggests that poliovirus 3C\textsuperscript{pro}
mediates cleavage at an additional site that remains to be determined. Similarly,
a second cleavage product of ~110 kDa was identified for ALIX using the FLAG
antibody, in addition to the TAILS-identified cleavage product of ~86 kDa.
Mutations at the TAILS-identified cleavage site for FLAG-RIPK1-HA failed to
block cleavage, generating a single cleavage product of same molecular weight
as the wild type version. This result suggests that RIPK1 is cleaved at a nearby
different site or at multiple sites either directly or indirectly by 3C\textsuperscript{pro}. 
TAILS-generated 3C\textsuperscript{pro} candidate substrates are cleaved during virus infection

To examine whether the cleavage of the target substrates occurs during virus infection, HeLa cells were either mock- or poliovirus-infected, harvested at different times after infection and immunoblotted for specific proteins (Fig. 6A). Poliovirus infections were performed at an MOI of 10 and monitored by detection of VP1 expression. Cleavage of G3BP1, a known substrate of 3C\textsuperscript{pro}, was observed starting at 3 hours post infection (h.p.i.), producing the expected cleavage product (Fig. 6A)\(^\text{(41)}\). Similarly, cleavage fragments of ALIX, ACLY, hnRNP K, RIPK1, GBF1 and PFAS were detected by 3 to 5 h.p.i. (Fig. 6A).

There was no detectable decrease in the full-length ALIX, ACLY, hnRNP K, RIPK1, GBF1 and PFAS proteins, suggesting that only a subset of these target proteins is cleaved during infection. In contrast, full-length p115 decreased dramatically and was barely detected at 7 h.p.i. Cleavage fragments of p115 were not detected by this C-terminal antibody, similar to that observed \textit{in vitro} (Figs. 4 and 6A). However, using the N-terminal p115 antibody, we detected a cleavage product of \(~100\) kDa, which is the predicted mass of the N-terminal fragment based on the TAILS results (Figs. 4 and 6A). Thus, the N-terminal cleavage product of p115 is stable during virus infection. Cleavage products of ACLY, PFAS, hnRNP K and ALIX were of similar molecular weight to the cleavage products observed \textit{in vitro} (Fig. 4). Immunoblotting for RIPK1 detected a smaller protein fragment in infected cells compared to that \textit{in vitro}, consistent with the idea that RIPK1 may have multiple cleavage sites (Figs. 4 and 6A).
We next examined whether the TAILS-identified substrates cleaved during poliovirus infection were also targeted in CVB3-infected HL-1 cardiomyocytes. We previously showed that TDP-43 and hnRNP M are cleaved in CVB3-infected HeLa cells and in cardiomyocytes (44, 45). Using antibodies that cross-reacted with mouse proteins, immunoblots showed that RIPK1 and hnRNP K were also cleaved in CVB3-infected HL-1 cells at 12 h.p.i. (Fig. 6B). These results confirmed that a subset of TAILS-identified candidate substrates are cleaved in both poliovirus-infected HeLa cells and CVB3-infected HL-1 cells.

We assessed the status of the wild type and mutant target substrates that were resistant to 3C<sub>pro</sub> cleavage <em>in vitro</em> (Fig. 5B) in virus-infected cells. HeLa cells were transfected with either wild type or mutant FLAG-HA expression constructs for 48 hours, followed by poliovirus infection. Immunoblotting for wild type FLAG-tagged proteins detected cleavage fragments of ALIX, PFAS and hnRNP K, similar to that observed <em>in vitro</em> (Fig. 6C), indicating that the cleaved N-terminal protein fragments are stable and persist during infection. In contrast, several cleavage fragments of FLAG-ACLY were detected that were not observed in the <em>in vitro</em> cleavage assay, suggesting that this protein is cleaved at multiple sites during infection, likely by another protease. The full-length FLAG-p115-HA decreased in expression during infection (Fig. 6C), similar to that observed using the p115 antibody (Fig. 6A), however, we also detected a faint ~100 kDa band, consistent with observations that the N-terminal cleavage product of p115 is partially stable during infection (Fig. 6C). In contrast to wild type, FLAG-tagged mutant ACLY, PFAS, hnRNP K, ALIX, and p115 resistant to
Caspases are activated during enterovirus infections and poly-ADP ribose polymerase (PARP) is cleaved in poliovirus-infected cells (47, 48). PARP cleavage can be prevented by z-VAD treatment in poliovirus-infected cells (45). To assess whether cleavage of the target substrates is a result of caspase activity, we subjected poliovirus-infected cells with z-VAD (Fig. 7). Cleavage or a reduction in full-length protein was still observed for all candidates in poliovirus-infected cells treated with z-VAD. Interestingly, a second cleavage product of ~90 kDa was observed for ACLY in poliovirus-infected cells treated with DMSO, in addition to the previously observed 65 kDa cleavage product (Fig. 6). z-VAD treatment eliminated the 90 kDa cleavage product in poliovirus-infected cells, indicating that a subset of ACLY is targeted by caspases (Fig. 7). Thus, these results further support that the majority of the cleavages on the target proteins identified by TAILS are due to 3Cpro activity.

Depletion of 3Cpro-targeted substrates affect virus infection

We next explored the biological significance of the target substrates during virus infection using a siRNA knockdown approach. Transfection of HeLa cells with substrate specific siRNAs for 24-72 hours led to knockdown of each protein as compared to cells transfected with scrambled siRNAs (Fig. 8). Following knockdown, cells were challenged with poliovirus for 7 hours, and the media and
cells were subsequently harvested to measure both extracellular and intracellular viral yields by plaque assay. Knockdown of RIPK1, p115 and hnRNP K led to a three-seven fold decrease in extracellular viral yield (Fig. 8). Similarly, knockdown of hnRNP K and p115 resulted in a two- and five-fold decrease in intracellular viral yield, respectively, indicating a prominent role of these proteins in promoting virus replication. Although extracellular viral yield was decreased by RIPK1 knockdown, intracellular viral yields remained unchanged, indicating a possible role for RIPK1 in viral assembly or release. In contrast, knockdown of PFAS resulted in a two- and four-fold increase in intracellular and extracellular virus production, respectively, suggesting that PFAS may be antiviral. Viral yields following either ALIX or ACLY knockdown were not affected. Thus, our in vitro TAILS analysis has revealed novel 3C<sup>pro</sup> substrates that modulate poliovirus infection.

p115 facilitates poliovirus infection

p115 is a vesicle membrane tethering protein that facilitates biogenesis and maintenance of the Golgi apparatus, and is involved in regulating the transport of COPI and COPII vesicles between the ER and the cis-Golgi network as well as in intra-Golgi transport (49-52). p115 interacts with several Golgi-associated proteins including other tethering proteins, GM130 and giantin, the ARF1 guanine nucleotide exchange factor, GBF1, and the small GTPase, Rab1b, to modulate these functions (53, 54). We showed that p115 is cleaved to near completion during poliovirus infection, and that siRNA-mediated knockdown...
of p115 by results in a decrease in viral yield (Figs. 6A and 8), thus revealing a novel pro-viral factor of poliovirus infection. To assess the biological function of p115 during infection further, we first assessed its subcellular localization during poliovirus infection by immunofluorescence (Fig. 9A). Poliovirus infection disrupts ER to Golgi trafficking, resulting in disruption of the Golgi complex and dispersion of Golgi-associated proteins, such as GM130 (55). Similarly, in poliovirus-infected cells, p115 began to disperse from a Golgi-like staining pattern at 3 h.p.i.. By 5 h.p.i., p115 was completely re-distributed throughout the cytoplasm, forming a multiple punctate pattern (Fig. 9A). At 7 h.p.i., p115 was barely detected, which correlates with the loss in full-length p115 observed at 7 h.p.i. by immunoblotting using the C-terminal p115 antibody (Fig. 6A). These results are consistent with a previous report that EGFP-tagged p115 becomes dispersed in poliovirus-infected HeLa cells (56). Given that dispersion of p115 was detected 3 h.p.i., prior to detection of its cleavage at 5 h.p.i., we suspect that cleavage of p115 occurs after its relocalization from the Golgi (Fig. 6A). Thus, this data confirms that endogenous p115 becomes displaced from the Golgi in poliovirus-infected cells.

We next assessed whether depletion of p115 decreases viral protein production by immunoblot analysis (Fig. 9B). Synthesis of VP1 was monitored over time throughout poliovirus infection in HeLa cells pre-treated with either scrambled or p115 siRNA. p115 depletion showed a reproducible delay in VP1 synthesis, most noticeably at 5 h.p.i. Similarly, loss of p115 decreased poliovirus genomic RNA accumulation by ~25% at 5.5 and 7 h.p.i. (Fig. 9C) demonstrating
that loss of p115 attenuates both viral protein and genomic RNA synthesis. Altogether, this data provides additional evidence to support a facilitative role for p115 in poliovirus replication.

Cleavage of p115 modulates its association with replication sites

To determine whether cleavage of p115 is important for infection, we expressed wild type or cleavage resistant p115 (QG832EP) in poliovirus-infected HeLa cells. Towards this, wild type and mutant forms of p115 were cloned in frame with an N-terminal GFP into a mammalian expression vector (Fig. 10A, WT and QG832EP GFP-p115). Cells were transfected with wild type and mutant GFP-p115 followed by infection with poliovirus. Immunoblotting of p115 mock-infected cells showed that wild type and QG832EP GFP-p115 were expressed to similar levels as endogenous p115 (Fig. 10A). In poliovirus-infected cells, wild type but not the mutant QG832EP GFP-p115 was cleaved at 8 and 10 h.p.i. (Fig. 10B). In mock-infected cells, both wild type and QG832EP GFP-p115 clustered near the nucleus that overlapped with Golgin-97 and/or GM130 signal, consistent with Golgi localization (Fig. 11) (57, 58) and suggesting that the GFP tag does not disrupt p115 subcellular localization.

Poliovirus replication requires viral 3A protein as well as several cellular proteins including GBF1 (59). During poliovirus infection, GBF1 transiently co-localizes with dsRNA and 3A protein, which are markers of replication sites (60-62). dsRNA can be detected by immunofluorescence using a dsRNA antibody (60). Given that p115 interacts with GBF1, we asked whether cleavage of p115 is
a prerequisite for GBF1 interaction with dsRNA during poliovirus infection. FACS-sorted wild type or QG832EP GFP-p115 cells were infected with poliovirus and subsequently fixed and stained with GBF1 and dsRNA antibodies (Fig. 10C and 10D). Both wild type and QG832EP GFP-p115 were dispersed during poliovirus infection, further suggesting that cleavage of p115 is not required for Golgi fragmentation (Fig. 12A). We monitored infection at 8 hours after virus absorption, a time when wild type but not QG832EP GFP-p115 is cleaved (Figs. 10B). At 8 h.p.i., GBF1 signal overlapped with p115 signal in cells expressing wild type GFP-p115 with an average Mander’s Correlation Coefficient (MCC) MCC of 0.45, indicating that only 45% of GBF1 signal overlapped with wild type GFP-p115 (Fig. 10C). By contrast, in cells expressing QG832EP GFP-p115, the fraction of GBF1 that overlapped with mutant GFP-p115 was reproducibly higher (MCC=0.74) (Fig. 10C). Similarly, the fraction of p115 that overlapped with dsRNA was higher in cell expressing QG832EP GFP-p115 (MCC=0.59) compared to wild type GFP-p115 cells (MCC=0.33) (Fig. 10D). The fraction of GBF1 signal that overlapped with dsRNA signal in cells expressing wild type GFP-p115 occurred with a Pearson’s Coefficient of 0.66 and an average MCC of 0.56, indicating that only 56% of GBF1 signal overlapped with dsRNA (Fig. 12B). These results are consistent with previous reports that GBF1 associates with dsRNA during poliovirus infection (60). The fraction of GBF1 overlap with dsRNA was similar to that in QG832EP GFP-p115 expressing cells compared to wild type GFP-p115 (Fig. 12B). In summary, these results show that preventing p115 cleavage during poliovirus infection increases the association of the fraction of
GBF1 with p115 and the fraction of p115 with dsRNA, thus suggesting that cleavage of p115 may regulate the association of itself and/or GBF1 with replication complexes.

Cleavage of p115 promotes poliovirus replication

Given that p115 cleavage may affect replication complexes, we investigated whether cleavage of p115 is required for poliovirus infection. Towards this, FACS-sorted HeLa cells expressing wild type or QG832EP GFP-p115 were infected with poliovirus at an MOI 1 and viral titres were monitored at 8, 12, 16 and 20 h.p.i. (Fig. 13A). Expression of the cleavage-resistant GFP-p115 (QG832EP) consistently decreased viral yield compared to wild type GFP-p115, with an approximate 4-fold and 2-fold decrease in intracellular and extracellular titres, respectively, observed at 20 h.p.i. (Fig. 13A). Supporting this result, expression of QG832EP GFP-p115 reduced poliovirus RNA synthesis by ~25% compared to that in cells expressing wild type GFP-p115 (Fig. 13B). In summary, these results demonstrate that cleavage of p115 promotes poliovirus infection.
Discussion

In this, the first comprehensive study using a gel-free proteomics approach that identifies and validates functional host targets of a viral protease, we identified 72 and 34 novel candidate host protein targets of poliovirus and CVB3 3C\textsuperscript{pro}, respectively. Knockdown and overexpression validation studies revealed that these target proteins modulate virus infection and so are biologically relevant. For example, cleavage of the vesicle tethering protein p115 facilitates poliovirus infection and modulates the assembly of host proteins at replication sites. The identification of novel targets of 3C\textsuperscript{pro} adds to the growing list of known substrates that provides a more comprehensive view of the virus-host interactions that contribute to enterovirus infection.

Many substrates, such as PFAS, hnRNP K, and ALIX, generated similar cleavage products \textit{in vitro} and during virus infection, and these cleavage products were stable in virus-infected cells. Although cleaved by 3C\textsuperscript{pro}, the cleavage products of RIPK1 and ACLY were not of similar mass \textit{in vitro} compared to during infection (Figs. 4 and 6A). We previously reported differences in cleavage product production of hnRNP M during both poliovirus and CVB3 infection compared to \textit{in vitro} cleavage (45). Differences in cleavage pattern \textit{in vitro} compared to infection can manifest for many reasons, e.g., the protein is cleaved by 3C\textsuperscript{pro} at alternate cleavage site(s) that were not identified for technical reasons by mass spectrometry, or targeted by 2A\textsuperscript{pro} or cellular proteases after the initial and often destabilizing cleavage event. Although we validated cleavage of several 3C\textsuperscript{pro} high confidence candidate substrates
identified by TAILS in virus-infected cells, it was not surprising that a few of the top candidate substrates were cleaved \textit{in vitro} but not during virus infection (e.g. Actin, eIF3F, and Fascin, Table S6, data not shown), indicating that an \textit{in vitro} cleavage assay approach does not fully recapitulate \textit{in vivo} infection as expected.

TAILS, like all proteomics techniques, can have limitations, hampering its capacity to identify all possible substrates of viral proteases. For example, post-translational modifications at the N-terminus, such as acetylation or cyclization, preclude dimethylation labeling, can reduce the number of quantifiable peptides by mass spectrometry. Other stochastic reasons include duty cycle times of the mass spectrometer that can lead to undersampling, resulting in missed peptides. Moreover, 3C\textsuperscript{pro}-derived peptides may also not be of suitable mass and/or achieve sufficient ionization to be identified by mass spectrometry. Indeed, predicted trypsin-digested peptides generated from known 3C\textsuperscript{pro} substrates such as G3BP1, PAPB and AU-rich element RNA binding protein 1 (AUF1), are either too short or long for efficient ionization and fragmentation to be confidently detected by mass spectrometry (Table S12) (38, 41, 63). Thus, although TAILS identified PTB, a known substrate of poliovirus 3C\textsuperscript{pro}, and \~{}100 novel candidate protein targets, it is likely that more host targets are yet to be identified through novel alternate proteomic strategies and underscores the potential number of impactful host proteins that are targeted by 3C\textsuperscript{pro}.

Our two-prong TAILS approach to identify substrates of 3C\textsuperscript{pro} of two enteroviruses was chosen to inventory distinct cleavage specificities and possibly
identify common substrates. The IceLogo analysis of the 3C<sup>pro</sup> cleavage sites suggests that 3C<sup>pro</sup> is capable of accepting a wider range of amino acids within its active site and therefore allowing for cleavage of a broader range of substrates (Fig. 3) (12). Interestingly, we identified three common proteins (hnRNP K, hnRNP M, and PFAS) as high confidence candidate substrates of both CVB3 and poliovirus 3C<sup>pro</sup>, which adds to the list of host protein substrates identified as common targets of both 3C<sup>pro</sup> (45). Whether other host candidate substrates are cleaved among all enterovirus infections warrants further investigation. It is likely that cleavage of a subset of host proteins is strategic whereas others are specific to each enterovirus life cycle, the infected host cell type, and/or its pathogenesis.

Cleavage of some of the validated TAILS-identified candidate targets contributes to virus infection (Fig. 8), emphasizing the utility of TAILS in identifying novel host determinants for enterovirus infection. Both p115 and GBF1, which have been previously characterized during poliovirus infection, are substrates of poliovirus 3C<sup>pro</sup> during infection (Fig. 4, 6A). Confirming the central role that p115 plays in viral replication, we found that both knockdown of p115 during virus infection or overexpression of a noncleavable mutant p115 decreased poliovirus titres (Figs. 8 and 13). Both p115 and GBF1 have been associated with a role in enterovirus replication (64). Enterovirus replication occurs on membranous replication organelles that form during infection via a combination of membrane remodeling of Golgi-ER complexes and reorganization of lipid metabolic pathways to generate replication membranes with unique lipid
compositions (64, 65). What is the role of p115 cleavage in virus-infected cells? Our results showed that preventing cleavage of p115 promotes GBF1 association with dsRNA (Fig. 12B, C), a marker of replication intermediates. At first, this observation seems counterintuitive as expression of the cleavage-resistant mutant resulted in lower viral yield. Given that a previous report showed that GBF1, which is an essential factor for viral replication, transiently overlaps with dsRNA early in infection (60), cleavage of p115 may ensure that the association of GBF1 with dsRNA is transient during virus infection. Consistent with this idea, preventing cleavage of p115 resulted in a greater fraction of GBF1 overlapping with cleavage-resistant p115 compared to cells that express wild type p115 (Fig. 10C). Given that p115 can interact with GBF1 directly (53), it will be important to determine the affinity of the cleaved p115 and full-length p115 interactions with GBF1. It is worth noting that the presence of the endogenous p115 may mask effects of expression of the cleavage resistant mutant in infected cells, possibly underestimating effects of cleavage of p115 during infection. One enticing possibility is that stable cleaved fragments (N or C-terminal) of p115 may have a novel function unrelated to its full-length function. Indeed, it has been demonstrated that viral protease-mediated cleaved fragments of hnRNP M, G3BP1, PCBP2 adopt alternate functions that promote virus replication and translation (19, 40, 45, 66). Given that both depletion and blocking cleavage of p115 decreases viral replication, and that the N-terminal fragment of p115 is relatively stable during poliovirus infection, cleavage of p115 may lead to stable
cleavage fragment(s) that are subverted during virus infection to support viral replication, possibly through interactions with viral replication complexes.

Another possible function is that p115 may contribute to blocking the secretory pathway during infection. Previous studies have shown that siRNA-mediated depletion of p115, cleavage of p115 by caspases, or expression of its C-terminal caspase cleavage fragment promotes fragmentation of the Golgi apparatus, impairment of secretory trafficking and induction of apoptosis (67, 68).

Cleavage of 3CPro is not through the caspase cleavage site of p115, TEKD757, which is relatively close to the 3CPro cleavage site (VEVQ832) (Fig. 7). Both GBF1 and p115 become dispersed within the cytoplasm during poliovirus infection (Figs. 10 and 12) (59, 60), indicating that the Golgi apparatus is fragmented in infected cells. Cleavage of p115 by 3CPro along with the expression of poliovirus 3A, 2BC, 2B and 2C, may contribute to Golgi disassembly and/or block the secretory pathway, thereby suppressing antiviral host cell responses, such as cytokine secretion and antigen presentation (55, 69-72).

TAILS has proven to be effective in identifying substrates of cellular proteases and in vivo and now for unbiased analysis of viral proteases and the consequences of specific substrates in infection. The TAILS proteomic approach has identified unique and some overlapping substrates for poliovirus and CVB3 3CPro, thus paving the way for ongoing studies into the roles of cleavage of the remaining novel host protein targets in enterovirus infection, many of which will likely have specific roles in blocking antiviral responses or in modulating cellular processes to hijack protein function for viral translation, replication or
Importantly, this unbiased TAILS approach can be applied to identify host cell substrates of other enterovirus proteinases and proteases from other viral families. Identification of host cell substrates of several proteases of different viral families will undoubtedly shed light into the common and varying strategies that viruses use to manipulate host cell processes for efficient virus infection.

**Materials and Methods**

**Protein purification**

His-tagged wild type and catalytically inactive mutant (Cys147Ala) poliovirus 3C\(^{pro}\) proteinases were purified as previously described (73).

**In vitro cleavage assay**

In vitro cleavage assays were performed as previously described using HeLa or HL-1 cell extracts (73).

**Cell culture and virus stocks**

HeLa cells (already-existing collection) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) at 37°C. Poliovirus (Mahoney type 1 strain NC_002058.3) was generated from a pT7pGemPolio poliovirus infectious clone as previously described (generously provided by Kurt Gustin, University of Arizona). HL-1 murine cardiac muscle cells (already-existing collection) were
cultured in Claycomb media (Sigma) supplemented with 10% FBS, 1% P/S, 2 mM L-glutamine, and 0.1 mM norepinephrine in ascorbic acid. Poliovirus and CVB3 (Kandolf strain M33854.1) were both propagated and titred in HeLa cells.

**Virus infections**

Virus was absorbed with HeLa or HL-1 cells at the indicated multiplicity of infection (MOI) for 1 h in serum-free DMEM or Claycomb media at 37 °C, then washed by phosphate buffered saline (PBS) and replaced with complete media. For virus infections in the presence of Z-Val-Ala-DL-Asp-fluoromethylketone (zVAD-FMK, Calbiochem), zVAD-FMK was added to serum-free DMEM containing virus to HeLa cells at a final concentration of 50 µM.

For plaque assays, intracellular and extracellular virus titres were measured from cell supernatant or cell pellet from virus–infected cells, respectively. Cell pellets were prepared by harvesting cells in serum-free DMEM following two washes with PBS and lysing by 3 cycles of freeze thawing. Plaque assays were prepared as previously described (73).

**Immunoblot analysis**

Equal amounts of protein were resolved by SDS-PAGE and transferred to a PVDF membrane. Antibodies used in this study were as follows: 1:2000 AIP1/ALIX (Millipore), 1:4000 RIPK1, 1:7500 hnRNP K (Santa Cruz), 1:1000 PFAS (Abcam), 1:2000 ACYL (Millipore), 1:1000 VDP p115/p115 (Novus Biologicals), 1:2000 p115 (abcam), 1:1000 GFB1 (abcam), 1:500 α-tubulin.
(Santa Cruz), 1:3000 G3BP1 (BD Transduction Science), 1:3000 VP1 (Dako), 1:2000 Flag (Sigma-Aldrich), 1:1000 PARP (Santa Cruz).

Plasmids and transfections

The full-length open reading frames of the following proteins were PCR-amplified and cloned into a p3XFlag-CMV-7.1 vector (Sigma) with a 3XHA-tag cloned downstream using XbaI and BamHI sites: hnRNP K (NM_002149), ALIX (NM_013374), RIPK1 (NM_003804), ACYL (NM_001096), PFAS (NM_012393) and p115 (NM_001290049). Constructs were verified by sequencing. Full-length wild type and mutant QG832EP p115 was cloned into a mEGFP-C1 vector using XhoI and BamHI sites.

For DNA transfections, HeLa cells were transfected with 1-2 µg of plasmid using Lipofectamine 2000 (Invitrogen) according to the manufacture’s protocol. Cells were transfected in antibiotic-free media for 5 h, then replaced with complete media for 24-48 h. For siRNA transfections, HeLa cells were transfected (30-40% confluency) with the following siRNAs using Lipofectamine RNAimax (Invitrogen): hnRNP K (Ambion; s6739, s6738, s6737), PFAS (Ambion; s10331, s10332, s10330), RIPK1 (Ambion; s16651), and p115 (Ambion; s16392, s16391, s16390). Knockdown efficiency was validated by Western blot analysis.

Immunofluorescence

HeLa cells on coverslips were fixed with cold 100% methanol for 10 min, washed three times with PBS and then blocked with 5% bovine serum albumin.
(BSA) in PBS for 1 h at room temperature or 10% goat serum in PBS overnight at 4 degrees, followed by 1 hour incubation with primary antibody with 1% BSA or 10% goat serum in PBS at room temperature. The primary antibodies were used as follows: 1:100 p115 (Novus Biologicals), 1:400 double stranded RNA (dsRNA, English & Scientific Consulting Bt), 1:100 GBF1 (abcam), 1:200 golgin97 (Cell Signaling), 1:100 GM130 (Cell Signaling), and 1:300 VP1 (Dako). Coverslips were washed three times with PBS then incubated with 1:500 secondary antibody (goat anti-rabbit or goat anti-mouse Texas red, and goat anti-mouse Alexa Fluor 488 (Life Technologies) with 1% BSA or 10% goat serum in PBS and Hoescht to stain for nuclei. Following three washes, coverslips were mounted onto slides using Prolong Gold Antifade Reagent (Life Technologies). Cells were imaged and analyzed using a Leica SP5 confocal microscope and pictures were taken using the LAS AF software (UBC Life Sciences Institute Imaging Core). For all images, Z-stacks of approximately 15 slices were captured. Fluorescent intensity of GFP-p115 WT and QG832EP expressing cells was measured using the FIJI software. Colocalization analysis was performed using the JACoP plug-in and calculated for three to five random fields of multiple cells. Pearson’s Coefficient and Mander's Correlation Coefficient were determined for wild type and QG832EP cells expressing GFP at similar fluorescent intensities.

Fluorescence-activated cell sorting analysis

HeLa cells were transfected with either wild type or mutant QG832EP.
mEGFP-C1 p115 for 24 h and prepared for fluorescence-activated cell sorting (FACS) analysis by pelleting cells following trypsinization and washing cells in FACS sorting buffer (2 mM EDTA, 2% FBS, 1xPBS) (UBC Life Sciences Institute FACS core facility). Cells were filtered and resuspended at 10-20 million cells/ml in FACS sorting buffer, then sorted by FACS using a FACSARia or BD Influx (BD Biosciences) cell sorter. GFP-expressing cells were collected and allowed to recover for 24 hours in DMEM supplemented with 20% FBS and 1% P/S.

Mass spectrometry data analysis

For samples analyzed on the Orbitrap XL and QExactive, spectra were matched to peptide sequences in the human UniProt protein database (October 2013) with appended standard laboratory and common contamination protein using the Andromeda algorithm as implemented in the MaxQuant software package v1.3.0.5 (74, 75) using standard settings with light and heavy (13CD2) dimethylation as quantitative labels on lysine and N-terminal residues in the first search, and only on lysine residues in the second. In the second search N-terminal modifications such as acetylation and pyroglutamation of Gln and Glu residues was used as a variable parameter. Carbamidomethylation (Cys) used as a fixed modification in both searches, as well as variable methionine oxidation (+15.994915 Da). The MS proteomics data in this paper have been deposited in the ProteomeXchange Consortium (proteomecentral.proteomexchange.org): data set identifier PXD008718.
Sequence logos were generated with IceLogo with a p-value of 5% (76).

Q-TOF data was similarly matched in MaxQuant version 1.5.2.8 against a Uniprot-derived murine proteome database (Oct 2013) with common contaminants added.

False discovery rate (FDR) was set to 0.01 at the protein level for all searches, and to 0.01 or 0.05 at the peptide or PSM level, depending on the experiment.

**Statistical analysis**

All statistical analyses were performed using GraphPad Prism. All graphs represent the mean ± standard deviation (s.d.). P values were determined using a paired t-test and statistical significance was determined as p<0.05.

**N-terminal TAILS proteomics**

TAILS was performed as previously described (29, 73). Briefly, equal amounts of HeLa or HL-1 cell lysates were incubated with either wild type or catalytically inactive Cys147Ala (C147A) mutant purified poliovirus or coxsackievirus 3C pro, respectively. Samples analyzed on the LTQ-Orbitrap XL were loaded onto a nano HPLC system (Thermo Scientific) coupled to an LTQ-Orbitrap hybrid mass spectrometer (LTQ-Orbitrap XL, Thermo Scientific) through a nanospray ionization source consisting of a fused-silica trap column (length, 2 cm; inner diameter, 100 μm; packed with 5 μm-diameter Aqua C-18 beads; Phenomenex), fused-silica fritted analytical column (length, 20 cm; inner
diameter, 50 μm; packed with 3 μm-diameter Reprosil-Pur C-18-AQ beads; Dr. Maisch GmbH) and a silica gold-coated spray tip (20 μm inner diameter, 6 μm diameter opening, pulled on a P-2000 laser puller; Sutter Instruments; coated on EM SCD005 Super Cool Sputtering Device, Leica Microsystems). Buffer A consisted of 0.5% acetic acid, and buffer B consisted of 0.5% acetic acid and 80% ACN. Gradients were run from 0% B to 15% B over 15 min, then from 15% B to 40% B in the next 65 min, then increased to 100% B over 10 min period, held at 100% B for 30 min. The LTQ-Orbitrap was set to acquire a full-range scan (m/z 350–1,800) at 60,000 resolution in the Orbitrap and to simultaneously fragment the top five peptide ions in each cycle in the LTQ (minimum intensity 200 counts). Parent ions were then excluded from MS/MS for the next 180 s. The Orbitrap was continuously recalibrated against protonated (Si(CH3)2O)6; at m/z = 445.120025 using the lock-mass function.

For TAILS using CVB3 3Cpro, peptides were eluted from Stage tips in 80% ACN, 0.1% formic acid, SpeedVac concentrated to near-dryness and dissolved in approximately 20 μl mobile phase A (0.1% formic acid). Peptides were analyzed with an EASY nLC-1000 HPLC system (Thermo Scientific) online coupled to an Impact II high resolution, high mass accuracy quadrupole time-of-flight (QTOF) system using a CaptiveSpray ion source (Bruker Daltonics) that was modified for minimal post-column dead volume as described (77). Peptides were loaded onto an in-house packed column (40 cm, 75 μm I.D.) packed with C18 material (Reprosil-Pur C-18-AQ beads 1.9 μm size; Dr. Maisch GmbH) and a silica gold-coated spray tip (20- μm inner diameter, 6- μm diameter opening, pulled on a P-
Author Contributions
J.M.J., A.D., T.K., N.S., and O.K. conducted the experiments. J.M.J., A.D., T.K., N.S., J.K., H.L., C.M.O., and E.J. designed the experiments and wrote the paper.

Acknowledgements
We thank Kurt Gustin (University of Arizona) for the pT7GEMpolio poliovirus infection clone, Richard Lloyd (Baylor College of Medicine) for the pET3Chc and pET-Cx2A plasmids and Robert Nabi (UBC) for kindly providing anti-GM130 antibody.
References

1. Turk B, Turk D, Turk V. 2012. Protease signalling: the cutting edge. EMBO J 31:1630-1643.
2. Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR. 2009. Viral and host proteins involved in picornavirus life cycle. Journal of biomedical science 16:103.
3. Racaniello VR. 2006. One hundred years of poliovirus pathogenesis. Virology 344:9-16.
4. Marchant D, Si X, Luo H, McManus B, Yang D. 2008. The impact of CVB3 infection on host cell biology. Curr Top Microbiol Immunol 323:177-198.
5. Garmaroudi FS, Marchant D, Hendry R, Luo H, Yang D, Ye X, Shi J, McManus BM. 2015. Coxsackievirus B3 replication and pathogenesis. Future microbiology 10:629-653.
6. Pelletier J, Sonenberg N. 1988. Internal Initiation of Translation of Eukaryotic Messenger-Rna Directed by a Sequence Derived from Poliovirus Rna. Nature 334:320-325.
7. Jacobson MF, Baltimore D. 1968. Polypeptide cleavages in the formation of poliovirus proteins. Proc Natl Acad Sci U S A 61:77-84.
8. Summers DF, Maizel JV, Jr. 1968. Evidence for large precursor proteins in poliovirus synthesis. Proc Natl Acad Sci U S A 59:966-971.
9. Palmenberg AC. 1990. Proteolytic processing of picornaviral polyprotein. Annu Rev Microbiol 44:603-623.
10. Gorbalenya AE, Donchenko AP, Blinov VM, Koonin EV. 1989. Cysteine proteases of positive strand RNA viruses and chymotrypsin-like serine proteases. A distinct protein superfamily with a common structural fold. FEBS Lett 243:103-114.
11. Mosimann SC, Cherney MM, Sia S, Plotch S, James MN. 1997. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J Mol Biol 273:1032-1047.
12. Blom N, Hansen J, Blaas D, Brunak S. 1996. Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Sci 5:2203-2216.
13. Toyoda H, Nicklin MJ, Murray MG, Anderson CW, Dunn JJ, Studier FW, Wimmer E. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45:761-770.
14. Liebig HD, Ziegler E, Yan R, Hartmuth K, Klump H, Kowalski H, Blaas D, Sommergruber W, Frasel L, Lamphear B, Rhoads R, Kuechler E, Skern T. 1993. Purification of two picornaviral 2A proteinases: interaction with eIF-4 gamma and influence on in vitro translation. Biochemistry 32:7581-7588.
15. Lamphear BJ, Yan R, Yang F, Waters D, Liebig HD, Klump H, Kuechler E, Skern T, Rhoads RE. 1993. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem 268:19200-19203.
16. Etchison D, Milburn SC, Edery I, Sonenberg N, Hershey JW. 1982. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J Biol Chem 257:14806-14810.

17. Laitinen OH, Svedin E, Kapell S, Nurminen A, Hytonen VP, Flodstrom-Tullberg M. 2016. Enteroviral proteases: structure, host interactions and pathogenicity. Reviews in medical virology 26:251-267.

18. Flather D, Semler BL. 2015. Picornaviruses and nuclear functions: targeting a cellular compartment distinct from the replication site of a positive-strand RNA virus. Frontiers in microbiology 6:594.

19. Perera R, Dajiogo S, Walter BL, Nguyen JH, Semler BL. 2007. Cellular protein modification by poliovirus: the two faces of poly(rC)-binding protein. J Virol 81:8919-8932.

20. Back SH, Kim YK, Kim WJ, Cho S, Oh HR, Kim JE, Jang SK. 2002. Translation of polioviral mRNA is inhibited by cleavage of polypyrimidine tract-binding proteins executed by polioviral 3C(pro). J Virol 76:2529-2542.

21. Rassmann A, Henke A, Zobawa M, Carlsah M, Saluz HP, Grabley S, Lottspeich F, Munder T. 2006. Proteome alterations in human host cells infected with coxsackievirus B3. J Gen Virol 87:2631-2638.

22. Zhang B, Seitz S, Kusov Y, Zell R, Gauss-Muller V. 2007. RNA interaction and cleavage of poly(C)-binding protein 2 by hepatitis A virus protease. Biochem Biophys Res Commun 364:725-730.

23. Hung HC, Wang HC, Shihi SR, Teng IF, Tseng CP, Hsu JT. 2011. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis 203:1784-1790.

24. Seipelt J, Liebig HD, Sommergruber W, Gerner C, Kuechler E. 2000. 2A proteinase of human rhinovirus cleaves cytokeratin 8 in infected HeLa cells. J Biol Chem 275:20084-20089.

25. Weng KF, Li ML, Hung CT, Shih SR. 2009. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathog 5:e1000593.

26. Urzainqui A, Carrasco L. 1989. Degradation of cellular proteins during poliovirus infection: studies by two-dimensional gel electrophoresis. J Virol 63:4729-4735.

27. Huesgen PF, Overall CM. 2012. N- and C-terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification. Physiologia plantarum 145:5-17.

28. Staes A, Impens F, Van Damme P, Rutten B, Goethals M, Demol H, Timmerman E, Vandekerckhove J, Gevaert K. 2011. Selecting protein N-terminal peptides by combined fractional diagonal chromatography. Nature protocols 6:1130-1141.

29. Kleifeld O, Doucet A, auf dem Keller U, Prudova A, Schilling O, Kainthana RK, Starr AE, Foster LJ, Kizhakkedathu JN, Overall CM. 2010. Isotopic labeling of terminal amines in complex samples identifies...
protein N-termini and protease cleavage products. Nature biotechnology 845
28:281-288.
30. Kleifeld O, Doucet A, Prudova A, auf dem Keller U, Gioia M, Kizhakkedathu JN, Overall CM. 2011. Identifying and quantifying proteolytic events and the natural N terminome by terminal amine isotopic labeling of substrates. Nature protocols 6:1578-1611.
31. Prudova A, Gocheva V, Auf dem Keller U, Eckhard U, Olson OC, Akkari L, Butler GS, Fortelny N, Lange PF, Mark JC, Joyce JA, Overall CM. 2016. TAILS N-Termimomics and Proteomics Show Protein Degradation Dominates over Proteolytic Processing by Cathepsins in Pancreatic Tumors. Cell reports 16:1762-1773.
32. Starr AE, Bellac CL, Dufour A, Goebeler V, Overall CM. 2012. Biochemical characterization and N-terminomics analysis of leukolysin, the membrane-type 6 matrix metalloprotease (MMP25): chemokine and vimentin cleavages enhance cell migration and macrophage phagocytic activities. J Biol Chem 287:13382-13395.
33. Marchant DJ, Bellac CL, Moraes TJ, Wadsworth SJ, Dufour A, Butler GS, Bilawchuk LM, Hendry RG, Robertson AG, Cheung CT, Ng J, Ang L, Luo H, Granville DJ, Dive V, McManus BM, Overall CM. 2014. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nat Med 20:493-502.
34. Klein T, Fung SY, Renner F, Blank MA, Dufour A, Kang S, Bolger-Munro M, Scurll JM, Priatel JJ, Schweigler P, Melkko S, Gold MR, Viner RI, Regnier CH, Turvey SE, Overall CM. 2015. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-kappaB signalling. Nature communications 6:8777.
35. Prudova A, auf dem Keller U, Butler GS, Overall CM. 2010. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteomics 9:894-911.
36. auf dem Keller U, Prudova A, Gioia M, Butler GS, Overall CM. 2010. A statistics-based platform for quantitative N-terminome analysis and identification of protease cleavage products. Mol Cell Proteomics 9:912-927.
37. Pallai PV, Burkhardt F, Skoog M, Schreiner K, Bax P, Cohen KA, Hansen G, Palladino DE, Harris KS, Nicklin MJ, Wimmer E. 1989. Cleavage of synthetic peptides by purified poliovirus 3C protease. J Biol Chem 264:9738-9741.
38. Kuyumcu-Martinez NM, Joachims M, Lloyd RE. 2002. Efficient cleavage of ribosome-associated poly(A)-binding protein by enterovirus 3C protease. J Virol 76:2062-2074.
39. Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R. 2004. Molecular pathology of inflammatory cardiomyopathy. Medical microbiology and immunology 193:101-107.
40. Fung G, Ng CS, Zhang J, Shi J, Wong J, Piesik P, Han L, Chu F, Jagdeo J, Jan E, Fujita T, Luo H. 2013. Production of a dominant-negative fragment due to G3BP1 cleavage contributes to the disruption of mitochondria-associated protective stress granules during CVB3 infection. PLoS One 8:e79546.

41. White JP, Cardenas AM, Marissen WE, Lloyd RE. 2007. Inhibition of cytoplasmic mRNA stress granule formation by a viral proteinase. Cell host & microbe 2:295-305.

42. Joachims M, Van Breugel PC, Lloyd RE. 1999. Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J Virol 73:718-727.

43. Kuyumcu-Martinez NM, Van Eden ME, Younan P, Lloyd RE. 2004. Cleavage of poly(A)-binding protein by poliovirus 3C protease inhibits host cell translation: a novel mechanism for host translation shutoff. Mol Cell Biol 24:1779-1790.

44. Fung G, Shi J, Deng H, Hou J, Wang C, Hong A, Zhang J, Jia W, Luo H. 2015. Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis. Cell Death Differ 22:2087-2097.

45. Jagdeo JM, Dufour A, Fung G, Luo H, Kleifeld O, Overall CM, Jan E. 2015. Heterogeneous Nuclear Ribonucleoprotein M Facilitates Enterovirus Infection. J Virol 89:7064-7078.

46. Kean KM, Teterina N, Girard M. 1990. Cleavage specificity of the poliovirus 3C protease is not restricted to Gln-Gly at the 3C/3D junction. J Gen Virol 71 (Pt 11):2553-2563.

47. Rebsamen M, Meylan E, Curran J, Tschopp J. 2008. The antiviral adaptor proteins Cardif and Trif are processed and inactivated by caspases. Cell Death Differ 15:1804-1811.

48. Carthy CM, Granville DJ, Watson KA, Anderson DR, Wilson JE, Yang D, Hunt DW, McManus BM. 1998. Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J Virol 72:7669-7675.

49. Allan BB, Moyer BD, Balch WE. 2000. Rab1 recruitment of p115 into a cis-SNARE complex: programming budding COPII vesicles for fusion. Science 289:444-448.

50. Alvarez C, Fujita H, Hubbard A, Sztul E. 1999. ER to Golgi transport: Requirement for p115 at a pre-Golgi VTC stage. J Cell Biol 147:1205-1222.

51. Waters MG, Clary DO, Rothman JE. 1992. A novel 115-kD peripheral membrane protein is required for intercisternal transport in the Golgi stack. J Cell Biol 118:1015-1026.

52. Nelson DS, Alvarez C, Gao YS, Garcia-Mata R, Fialkowski E, Sztul E. 1998. The membrane transport factor TAP/p115 cycles between the Golgi and earlier secretory compartments and contains distinct domains required for its localization and function. J Cell Biol 143:319-331.
53. Garcia-Mata R, Sztul E. 2003. The membrane-tethering protein p115 interacts with GBF1, an ARF guanine-nucleotide-exchange factor. EMBO Rep 4:320-325.

54. Monetta P, Slavin I, Romero N, Alvarez C. 2007. Rab11b interacts with GBF1 and modulates both ARF1 dynamics and COPI association. Mol Biol Cell 18:2400-2410.

55. Beske O, Reichelt M, Taylor MP, Kirkegaard K, Andino R. 2007. Poliovirus infection blocks ERGIC-to-Golgi trafficking and induces microtubule-dependent disruption of the Golgi complex. J Cell Sci 120:3207-3218.

56. Belov GA, Kovtunovych G, Jackson CL, Ehrenfeld E. 2010. Poliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1. Cellular microbiology 12:1463-1479.

57. Griffith KJ, Chan EK, Lung CC, Hamel JC, Guo X, Miyachi K, Fritzler MJ. 1997. Molecular cloning of a novel 97-kd Golgi complex autoantigen associated with Sjogren's syndrome. Arthritis Rheum 40:1693-1702.

58. Nakamura N, Rabouille C, Watson R, Nilsson T, Hui N, Sliusarewicz P, Kreis TE, Warren G. 1995. Characterization of a cis-Golgi matrix protein, GM130. J Cell Biol 131:1715-1726.

59. Belov GA, Altan-Bonnet N, Kovtunovych G, Jackson CL, Lippincott-Schwartz J, Ehrenfeld E. 2007. Hijacking components of the cellular secretory pathway for replication of poliovirus RNA. J Virol 81:558-567.

60. Richards AL, Soares-Martins JA, Riddell GT, Jackson WT. 2014. Generation of unique poliovirus RNA replication organelles. mBio 5:e00833-00813.

61. Wessels E, Duijsings D, Lanke KH, Melchers WJ, Jackson CL, van Kuppeveld FJ. 2007. Molecular determinants of the interaction between coxsackievirus protein 3A and guanine nucleotide exchange factor GBF1. J Virol 81:5238-5245.

62. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. 2006. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80:5059-5064.

63. Cathcart AL, Rozovics JM, Semler BL. 2013. Cellular mRNA decay protein AUF1 negatively regulates enterovirus and human rhinovirus infections. J Virol 87:10423-10434.

64. Belov GA, Sztul E. 2014. Rewiring of cellular membrane homeostasis by picornaviruses. J Virol 88:9478-9489.

65. Jackson WT. 2014. Poliovirus-induced changes in cellular membranes throughout infection. Current opinion in virology 9:67-73.

66. Costa-Mattioli M, Svitkin Y, Sonenberg N. 2004. La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol Cell Biol 24:6861-6870.
41
67. Puthenveedu MA, Linstedt AD. 2004. Gene replacement reveals that p115/SNARE interactions are essential for Golgi biogenesis. Proc Natl Acad Sci U S A 101:1253-1256.
68. Chiu R, Novikov L, Mukherjee S, Shields D. 2002. A caspase cleavage fragment of p115 induces fragmentation of the Golgi apparatus and apoptosis. J Cell Biol 159:637-648.
69. Sandoval IV, Carrasco L. 1997. Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 71:4679-4693.
70. Dodd DA, Giddings TH, Jr., Kirkegaard K. 2001. Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection. J Virol 75:8158-8165.
71. Doedens JR, Kirkegaard K. 1995. Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. EMBO J 14:894-907.
72. Deitz SB, Dodd DA, Cooper S, Parham P, Kirkegaard K. 2000. MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A. Proc Natl Acad Sci U S A 97:13790-13795.
73. Mohagheghi F, Prudencio M, Stuani C, Cook C, Jansen-West K, Dickson DW, Petrucelli L, Buratti E. 2015. TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. Hum Mol Genet.
74. Chen S, Zhang J, Duan L, Zhang Y, Li C, Liu D, Ouyang C, Lu F, Liu X. 2014. Identification of HnRNP M as a novel biomarker for colorectal carcinoma by quantitative proteomics. American journal of physiology. Gastrointestinal and liver physiology 306:G394-403.
75. Cui Y, Koirala D, Kang H, Dhakai S, Yangyuoru P, Hurley LH, Mao H. 2014. Molecular population dynamics of DNA structures in a bcl-2 promoter sequence is regulated by small molecules and the transcription factor hnRNP LL. Nucleic Acids Res 42:5755-5764.
76. Colaert N, Helsens K, Martens L, Vandekerckhove J, Gevaert K. 2009. Improved visualization of protein consensus sequences by iceLogo. Nature methods 6:786-787.
77. Beck S, Michalski A, Raether O, Lubeck M, Kaspar S, Goedecke N, Baessmann C, Hornburg D, Meier F, Paron I, Kulak NA, Cox J, Mann M. 2015. The Impact II, a Very High-Resolution Quadrupole Time-of-Flight Instrument (QTOF) for Deep Shotgun Proteomics. Mol Cell Proteomics 14:2014-2029.

1019
1020
1021
1022
**Figure Legends**

**Figure 1. High confidence candidate substrates of poliovirus and CVB3**

3C\textsuperscript{pro} identified by TAILS. (A) TAILS 3C\textsuperscript{pro} workflow. Proteome sample (500 ug) extracted from HeLa or HL-1 cell extracts were incubated poliovirus 3C\textsuperscript{pro} or CVB3 3C\textsuperscript{pro} (100 ng/ul), respectively, followed by isotopic dimethylation labeling and TAILS. High confidence substrates were determined by box plot-and-whiskers analysis of quantified heavy:light (H/L) ratio of dimethylation-labeled semi-tryptic neo-N-termini peptides. (B) Venn diagram illustrating the percentage of common high confidence substrates identified between TAILS analysis of poliovirus and CVB3 3C\textsuperscript{pro}. Select high confidence substrates of (C) poliovirus 3C\textsuperscript{pro} from HeLa cell extracts and of (D) CVB3 3C\textsuperscript{pro} from HL-1 cardiomyocytes. (E) Common peptides identified among both poliovirus and CVB3 3C\textsuperscript{pro} list of high confidence substrates. Peptides listed are statistically significant high H/L semi-tryptic neo-N-termini peptides. All high confidence substrates are listed in S4 and S8 Tables.

**Figure 2. In vitro cleavage assay of known enterovirus 3C\textsuperscript{pro} substrates.**

Immunoblot showing cleavage of G3BP1 (top left) and PABP (bottom) following an in vitro cleavage assay with HeLa cell lysates incubated with wild type or C147A mutant poliovirus (PV) 3Cpro at the times indicated. Immunoblot following cleavage of TDP-43 (top right) in HL-1 cell lysates incubated with wild type or C147A mutant coxsackievirus (CVB3) 3C\textsuperscript{pro}. cp, cleavage product.
Figure 3. Consensus cleavage site analysis of poliovirus and CVB3 3C\textsuperscript{pro} high confidence substrate peptides. Sequence logos of the ten amino acids positioned directly upstream (P1-P10) and downstream (P1'-P10') of the TAILS-identified peptides for (A) poliovirus 3C\textsuperscript{pro} and (B) CVB3 3C\textsuperscript{pro}.

Figure 4. Validation of TAILS high confidence substrates by \textit{in vitro} cleavage assay. \textit{Left:} HeLa cell lysates were incubated with purified wild type or mutant (C147A) poliovirus 3C\textsuperscript{pro} (100 ng/ul). Proteins were loaded on an SDS-PAGE and cleavage was assessed by immunoblotting. \textit{Right:} Schematics of corresponding high confidence candidate substrates, indicating key domains, the position of TAILS-predicted cleavage sites and the four amino acids position directly upstream (P1-P4) and downstream (P1'-P4') of the cleavage site. The predicted molecular weights of the cleavage protein fragments are shown below.

cp, cleavage product; N, N-terminal cleavage product; C, C-terminal cleavage product; GAT, glutamine amidotransferase; KH, hnRNP K homology; PRD, proline rich domain; GTC, golgi tethering complex; HUS, homology upstream of Sec7; HDS, homology downstream of Sec7; RHIM, RIP homotypic interaction motif; DCB, dimerization and cyclophilin binding.

Figure 5. Validation of TAILS-predicted cleavage site by \textit{in vitro} cleavage assay. (A) Schematic of cytomegolavirus (CMV) promoter-driven mammalian expression construct containing 3xFLAG and 3xHA fused in frame with the full-length candidate substrate. (B) Lysates from HeLa cells expressing the FLAG-
HA-tagged wild type or mutant candidate substrate were incubated with wild type or mutant poliovirus 3C<sup>pro</sup> and immuoblotted for FLAG. N, N-terminal cleavage product.

Figure 6. Cleavage of candidate substrates under virus infection. (A) HeLa cells were mock or poliovirus-infected (MOI 10) for the indicated times. (B) HL-1 cells were mock or CVB3-infected (MOI 50) for 12 h. Candidate substrate, viral structural protein VP1, and α-tubulin were assessed by immunoblotting. (C) HeLa cells transfected with wild type or mutant FLAG-HA constructs of candidate substrates were mock or poliovirus-infected (MOI 10) for 7 h. Lysates were immunoblotted with FLAG. h.p.i., hours post infection. cp, cleavage product; N, N-terminal cleavage product; C, C-terminal cleavage product.

Figure 7. Cleavage of candidate substrates in poliovirus-infected HeLa cells in the presence of zVAD-FMK. HeLa cells were infected with poliovirus (MOI 10) in the presence of DMSO or 50 µM zVAD-FMK (7 h.p.i.). Candidate proteins were detected by immunoblotting using the indicated antibody. N, N-terminal cleavage product; C, C-terminal cleavage product.

Figure 8. Candidate substrates identified by TAILS modulate poliovirus infection. HeLa cells were transfected with either scrambled (siSCX) or candidate specific siRNA for 24-72 h, followed by poliovirus infection (MOI 0.1) for 7 hours. Extracellular and intracellular virus was titred by plaque assay and
titres were calculated as plaque forming units (p.f.u/ml ± s.d., *p<0.05, ** p<0.01) from at least three independent experiments.

**Figure 9. p115 facilitates poliovirus infection.** HeLa cells were transfected with either scrambled (siSCX) or p115 (si-p115) siRNAs for 48 h, followed by poliovirus infection (MOI 1) for the indicated times. (A) Immunofluorescence of endogenous p115 in polioivirus-infected HeLa cells for the times indicated (left). Cells were permeabilized, fixed and co-stained for p115 (green, C-terminal antibody) and DNA (Hoescht). An image of HeLa cells stained for viral RNA using an anti-dsRNA antibody at 5 h.p.i. is shown to demonstrate the efficiency of infection at an MOI of 10 (right). (B) Immunoblots of p115, poliovirus structural protein VP1 and α-tubulin are shown. A representative gel is shown from three independent experiments. (C) Northern blot analysis of poliovirus genomic RNA from infected siSCX or si-p115 HeLa cells.

**Figure 10. Cleavage of p115 modulates GBF1 association with p115.** HeLa cells were transfected with either wild type (WT) or QG832EP GFP-p115 for 48 h and expression was assessed by immunoblot using an anti-p115 antibody in (A) uninfected HeLa cells and (B) following poliovirus infection (MOI 50) for the indicated times. Immunoblots of GFP, VP1, and α-tubulin are shown. (C) and (D) FACS-sorted HeLa cells expressing either wild type (WT) or QG832EP GFP-p115 were poliovirus-infected (MOI 50) for 8h. Cells were permeabilized, fixed and co-stained with GBF1 (blue) and dsRNA (red) antibodies. Representative
images from at least two independent experiments are shown for (C) GBF1 and GFP-p115 and (D) dsRNA and GFP-p115 (left). Dot plot graphs of the Manders' Correlation Coefficient calculated for (C) fraction of GBF1 overlap with GFP-p115 and (D) fraction of GFP-p115 overlap with dsRNA, in WT GFP-p115 (n=46) and QG832EP GFP-p115 (n=25) expressing cells (right). Shown are quantitations of a representative experiment that showed a reproducible trend from three independent experiments. * p<0.05, ** p<0.01.

Figure 11. Subcellular localization of WT and QG832EP GFP-p115 in HeLa cells. HeLa cells were transfected with either WT or QG832EP GFP-p115 for 48h. Cells were then fixed, permeabilized, and stained for goglin97 (red, top) or GM130 (red, bottom), and DNA (Hoescht).

Figure 12. Subcellular localization of WT and QG832EP GFP-p115 and GBF1 in HeLa cells during poliovirus infection. (A) FACS-sorted HeLa cells expressing either WT or QG832EP GFP-p115 were mock- or PV-infected (MOI 50) for 8h. Cells were permeabilized, fixed and co-stained with GBF1 (blue) and dsRNA (red) antibodies. (B) Representative images from at least two independent experiments are shown for the merged images of GBF1 and dsRNA, (C) Dot plot graphs of the Manders' Correlation Coefficient calculated for fraction of GBF1 overlap with dsRNA. Shown are quantitations of a representative experiment that showed a reproducible trend from three independent experiments.
Figure 13. Cleavage of p115 promotes poliovirus infection. (A) Intracellular and extracellular viral titres following poliovirus infection at MOI 1 at 8, 12, 16, and 20 h.p.i. of FACS-sorted HeLa cells transfected with wild type or QG832EP mutant GFP-p115. Average plaque forming units (p.f.u) +/- s.d. are shown from three independent experiments. ** p<0.001, * p<0.01. (B) Northern blot analysis of poliovirus genomic RNA in FACS-sorted HeLa cells transfected with WT or QG832EP mutant GFP-p115 and infected with poliovirus (MOI 5).
A

Proteome Sample

3C<sup>pro</sup>

<sup>13</sup>CD<sub>3</sub>O Heavy

3C<sup>pro</sup> C147A

<sup>13</sup>CH<sub>3</sub>O Light

Trypsin

Negative Selection

LC-MS/MS

B

Poliovirus 3C<sup>pro</sup> CVB3 3C<sup>pro</sup>

69 (67%)

31 (30%)

High Confidence Substrates

C

Select poliovirus 3C<sup>pro</sup> high confidence candidate substrates from HeLa cells

| Protein Description | Gene | P4-P1 | TAILS Peptide | Log2 H/L Ratio |
|---------------------|------|-------|---------------|----------------|
| Macrophage-capping protein | CAPG | AIPQ | SGSPFGSVQDGLHVWR | 7.79, 4.04, 4.03 |
| Receptor-interacting serine/threonine-protein kinase 1 | RIPK1 | YKGR | ILEIEGMCYL | 5.22 |
| ATP-citrate synthase | ACLY | AKNQ | ALKEAVFVPR | 5.54 |
| Ataxin-2 | ATXN2 | ASPQ | AGIPTAVAMPIAASPASNR | 2.75 |
| Polypyrimidine tract-binding protein 1 isoform 2 | PTBP1 | AIPQ | AAGLSVPVHGALAPLAPSSSAAAAAGR | 4.39, 4.29 |
| Programmed cell death 6-interacting protein | PDCD6IP | PAYQ | SSPAGHAPTPTTPAPR | 3.65 |
| General vesicular transport factor p115 | USO1 | VEVQ | GETTIATKTDVEGR | 3.45, 3.44 |
| Ribonuclease inhibitor | RNH1 | VLCQ | GLKDSQCLEALKLESCGVTSDNCRR | 3.55 |
| Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 | GFB1 | AGAQ | SDSELPSYHQNDIVSLDR | 1.03 |

D

Select CVB3 3C<sup>pro</sup> high confidence candidate substrates from HL-1 cardiomyocyte cells

| Protein Description | Gene | P4-P1 | TAILS Peptide | Log2 H/L Ratio |
|---------------------|------|-------|---------------|----------------|
| Microtubule-associated protein 1B | MAP1B | AAHQ | ASSSPPIDAATAEYGFR | 2.80 |
| Filamin-A | FLNA | NYPQ | GSOQTWPPIER | 4.24 |
| Lysosomal alpha-glucosidase | LYAG | IPLQ | GPSSLTTESR | 5.13 |
| Exosome Complex Component RRP45 | EXOS9 | VSQV | GEEVLYTFEER | 0.79 |
| DNA-directed RNA polymerase II subunit RPB2 | RPB2 | IDLQ | AEAGHASGEVEEPPR | 1.25 |

E

Common high confidence poliovirus and CVB3 3C<sup>pro</sup> peptides identified by TAILS

| Protein Description | Gene | P4-P1 | TAILS Peptide | Log2 H/L Ratio PV | Log2 H/L Ratio CVB3 |
|---------------------|------|-------|---------------|--------------------|---------------------|
| Heterogeneous nuclear ribonucleoprotein K | HNRNP | YEPQ | GGSGYDSYAGGR | 4.39, 4.29 | 3.35 |
| Phosphoribosylformylglycinamidine synthase | PFAS | VOVQ | GDNTSDLDFGAVQR | 4.94, 4.16, 3.62 | 3.81 |
| Heterogeneous nuclear ribonucleoprotein M | HNRNPM | IAKQ | GGGAGGSVPGIER | 4.75 | 3.35 |
Jagdeo Fig. 2

[Diagram showing protein bands for PV 3C\textsuperscript{pro} and CVB3 3C\textsuperscript{pro} with WT and C147A variants, along with HeLa and HL-1 cell lines, and time points 0, 5, 30, 60 minutes for PABP and G3BP1 proteins.]
Jagdeo Fig. 3

A

Poliovirus 3C

B

CVB3 3C

P value = 0.05

% difference

P4 P3 P2 P1 P1' P4' P3' P2'

B

A

Poliovirus 3C

CVB3 3C

P value = 0.05

% difference

P4 P3 P2 P1 P1' P4' P3' P2'
A 3X FLAG Target Protein 3X HA

B

Jagdeo_Fig 5

CMV

WT C147A WT C147A
WT I118A
WT C147A WT C147A

kDa

WT C147A WT C147A

PV 3C

Q472E/G473P

Q728E/S729P

Q832E/G833P

Q777E/A778P

FLAG-RIPK1-HA

FLAG-Alix-HA

FLAG-ACLY-HA

FLAG-PFAS-HA

FLAG-Alix

FLAG-ACLY

FLAG-ACLY-HA

FLAG-p115-HA

FLAG-hnRNP K-HA

FLAG-hnRNP K

FLAG-p115

FLAG-ACLY
| Gene         | Extracellular | Intracellular |
|-------------|---------------|---------------|
| siSCX       | p.f.u. (x 10^5) | *             |
| si-hnRNP K  |               |               |
| siSCX       | p.f.u. (x 10^5) | *             |
| si-hnRNP K  |               |               |
| siSCX       | p.f.u. (x 10^5) | **            |
| si-p115     |               |               |
| siSCX       | p.f.u. (x 10^5) |               |
| si-p115     |               |               |
| siSCX       | p.f.u. (x 10^5) |               |
| si-p115     |               |               |
| siSCX       | p.f.u. (x 10^5) |               |
| si-p115     |               |               |
| siSCX       | p.f.u. (x 10^5) |               |
| si-p115     |               |               |
| siSCX       | p.f.u. (x 10^5) |               |
| si-p115     |               |               |

**Note:** * indicates a significant difference, ** indicates a highly significant difference.
Figure 10

(A) Schematic of GFP-p115 and p115 expression. Untransfected (untr) and p115-transfected (WT) cells were treated with mock or polio virus for 6, 8, or 10 h.p.i. and anti-p115 (35 kDa) and TUB (55 kDa) western blots were performed. **p < 0.01 vs. mock.

(B) Western blot analysis of GFP-p115 and p115 expression in mock and polio virus-infected cells. **p < 0.01 vs. mock.

(C) Co-localization of GBF1 and p115. Manders coefficient analysis showed significant co-localization of GBF1 and p115, indicated by *p < 0.05 vs. WT.

(D) Co-localization of p115 and dsRNA. Manders coefficient analysis showed significant co-localization of p115 and dsRNA, indicated by **p < 0.01 vs. WT.
Jagdeo Fig. 11

WT
GFP-p1
15 Golgin97 Dapi Merge
Q832E/G833P
WT
GFP-p1
15 GM130 Dapi Merge
Jagdeo Fig. 12

(A) 8H

|          | WT        | Q832E/ G833P | WT        | Q832E/ G833P |
|----------|-----------|--------------|-----------|--------------|
| GFP      |           |              |           |              |
| -p15     |           |              |           |              |
| dsRNA    |           |              |           |              |
| GBF1     |           |              |           |              |
| Merge    |           |              |           |              |
| Dapi     |           |              |           |              |

(B) Merge, GBF1, dsRNA

(C) Manders Coefficient

GBF1 co-localization with dsRNA

Scale bars: 20 μm
A

\[
\begin{array}{c}
\text{Intracellular} \\
8 & 12 & 16 & 20 \\
\bullet \text{GFP-p115(WT)} \\
\Delta \text{GFP-p115(QG832EP)}
\end{array}
\]

\[
\begin{array}{c}
\text{Extracellular} \\
8 & 12 & 16 & 20 \\
2.5 & \ast & \ast
\end{array}
\]

B

\[
\begin{array}{c}
\text{bps} \\
7000 - \\
\text{mock} \\
\text{GFP-p115(WT)} \\
\text{GFP-p115(QG832EP)}
\end{array}
\]

Poliovirus RNA

GAPDH
Table 1. Summary of total peptide and proteins identified by TAILS analysis of poliovirus and CVB3 3C<sup>pro</sup>.

### Poliovirus 3C<sup>pro</sup> in Hela cell lysates

| Instrument  | N | Total Peptides | Unique Peptides | Unique Proteins | High Confidence Substrates |
|-------------|---|----------------|-----------------|-----------------|--------------------------|
| OrbiXL      | 3 | 627            | 534             | 444             | 10                       |
| QExactive   | 2 | 1778           | 1741            | 1059            | 37                       |
| QToF        | 2 | 1077           | 759             | 614             | 10                       |
| Orbi+QExactive | 5 | 2253           | 2224            | 1239            | 15                       |
| Total (Unique) | 7 | 3482           | 3210            | 1965            | 72                       |

### Coxsackievirus 3C<sup>pro</sup> in HL-1 cell lysates

| Instrument  | N | Total Peptides | Unique Peptides | Unique Proteins | High Confidence Substrates |
|-------------|---|----------------|-----------------|-----------------|--------------------------|
| QExactive   | 3 | 364            | 347             | 240             | 34                       |